For the millions of adults living with liver cirrhosis, a common and often overlooked viral infection may be silently pushing them toward catastrophic organ failure. Hepatitis E virus — widely dismissed as a self-limiting illness in healthy populations — appears to carry dramatically different consequences for those with already-compromised liver architecture, challenging the clinical assumption that HEV is a low-risk pathogen in Western healthcare settings.
This retrospective single-center analysis, spanning a decade of inpatient data, identified 32 cirrhotic patients hospitalized with acute HEV infection. The outcomes were striking: 50% developed acute-on-chronic liver failure (ACLF), with a 31.3% fatality rate among that subgroup and 18.8% requiring emergency liver transplantation. Beyond these hospitalized cases, the researchers systematically screened 249 serum samples collected during 184 separate episodes of acute hepatic decompensation, finding that approximately 4.4% were attributable to active HEV infection via IgM seropositivity or detectable HEV-RNA. A complementary seroprevalence analysis of 332 patients with advanced cirrhosis revealed prior HEV exposure in 67.2%, underscoring how frequently this virus circulates through this vulnerable population.
These findings carry meaningful clinical weight. ACLF is one of the most lethal acute events in hepatology, with 90-day mortality often exceeding 50% depending on grade — making identification of preventable triggers essential. HEV is a zoonotic pathogen transmitted primarily through undercooked pork products and is dramatically underdiagnosed in European clinical practice because routine workups rarely include HEV serology. A licensed HEV vaccine (Hecolin) exists and has demonstrated efficacy, though it remains unavailable in most Western countries. This study's primary limitation is its single-center, retrospective design, which constrains causal inference and generalizability. The 4.4% trigger rate, while modest in absolute terms, becomes clinically significant given HEV's preventability. This work is best characterized as a confirmatory and urgency-elevating contribution to a growing body of evidence advocating for routine HEV screening and vaccine access in cirrhotic patients.